Setterwalls has advised Amniotics AB (publ) (”Amniotics”) in connection with the listing on Nasdaq First North Growth Market. The trading in Amniotics’ shares and warrants on Nasdaq First North Growth Market commenced on 6 July 2021.
Amniotics is a biopharma company developing cell therapy drugs based on amniotic fluid from planned cesarean sections for treatment of specific diseases with high unmet needs. Amniotics focuses on so-called mesenchymal stem cells (MSC), derived from different tissues of the neonatal baby. Amniotics has an approved manufacturing facility to produce advanced therapy medicinal products and Amniotics is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies.
In connection with the listing, an offering of 1,463,415 units was made to the general public in Sweden, Norway and Finland, and to institutional investors in Sweden and abroad. Through the offering, Amniotics receives issue proceeds of approximately SEK 60 million before issue costs. In addition, Amniotics may receive additional issue proceeds of a maximum of approximately SEK 34.4 million before issue costs, provided that all warrants issued in connection with the offering are exercised for subscription of new shares in Amniotics.
Setterwalls acted as legal advisor to Amniotics in the listing process.